Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Oncologie Launches with $16.5 Million for IO Combinations in China and the US

publication date: Jun 7, 2018

Oncologie, a Boston-Shanghai startup, launched operations with $16.5 million in a seed financing led by Pivotal bioVenture Partners China. Oncologie plans to improve cancer care by licensing and partnering innovative combination drugs that improve the efficacy of immune checkpoint inhibitors. It has already made deals for two clinical-stage drug candidates. Oncologie will take advantage of China's recent regulatory changes by conducting parallel clinical development in China and the US, bringing its IO products to the world's two largest markets simultaneously. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital